Summary of Significant Accounting Policies (Tables)
|
9 Months Ended |
Sep. 30, 2020 |
| Accounting Policies [Abstract] |
|
| Schedule of cash and cash equivalents |
| | |
September 30, 2020 | | |
December 31, 2019 | |
| Cash and cash equivalents | |
$ | 34,364,560 | | |
$ | 16,350,237 | |
| Restricted cash | |
| 182,892 | | |
| 174,950 | |
| Total cash, cash equivalents and restricted cash | |
$ | 34,547,452 | | |
$ | 16,525,187 | |
|
| Schedule of marketable securities |
| | |
Amortized Cost | | |
Gross Unrealized Losses | | |
Gross Unrealized Gains | | |
Fair Value | |
| September 30, 2020: | |
| | |
| | |
| | |
| |
| Money Market Funds included in Cash Equivalents | |
$ | 4,962,810 | | |
$ | - | | |
$ | - | | |
$ | 4,962,810 | |
| U.S. Government Agency Securities | |
| - | | |
| - | | |
| - | | |
| - | |
| Corporate Securities | |
| 2,375,059 | | |
| (435 | ) | |
| 497 | | |
| 2,375,121 | |
| Commercial Paper | |
| 299,636 | | |
| - | | |
| 13 | | |
| 299,649 | |
| Subtotal | |
| 2,674,695 | | |
| (435 | ) | |
| 510 | | |
| 2,674,770 | |
| Total September 30, 2020 | |
$ | 7,637,505 | | |
$ | (435 | ) | |
$ | 510 | | |
$ | 7,637,580 | |
| December 31, 2019: | |
| | | |
| | | |
| | | |
| | |
| Money Market Funds included in Cash Equivalents | |
$ | 3,472,043 | | |
$ | - | | |
$ | 51 | | |
$ | 3,472,094 | |
| U.S. Government Agency Securities | |
| 2,691,091 | | |
| (42 | ) | |
| 869 | | |
| 2,691,918 | |
| Corporate Securities | |
| 6,058,265 | | |
| (1,438 | ) | |
| 440 | | |
| 6,057,267 | |
| Commercial Paper | |
| 3,234,583 | | |
| (16 | ) | |
| 405 | | |
| 3,234,972 | |
| Subtotal | |
| 11,983,939 | | |
| (1,496 | ) | |
| 1,714 | | |
| 11,984,157 | |
| Total December 31, 2019 | |
$ | 15,455,982 | | |
$ | (1,496 | ) | |
$ | 1,765 | | |
$ | 15,456,251 | |
|
| Schedule of carrying and fair value of financial assets |
| | |
Carrying Value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| September 30, 2020: | |
| | |
| | |
| | |
| |
| Money Market Funds and Cash Equivalents | |
$ | 4,962,810 | | |
$ | 4,962,810 | | |
$ | - | | |
$ | - | |
| U.S. Government Agency Securities | |
| - | | |
| - | | |
| - | | |
| - | |
| Corporate Securities | |
| 2,375,121 | | |
| - | | |
| 2,375,121 | | |
| - | |
| Commercial Paper | |
| 299,649 | | |
| - | | |
| 299,649 | | |
| - | |
| Subtotal | |
| 2,674,770 | | |
| - | | |
| 2,674,770 | | |
$ | - | |
| Total September 30, 2020 | |
$ | 7,637,580 | | |
$ | 4,962,810 | | |
$ | 2,674,770 | | |
$ | - | |
| December 31, 2019: | |
| | | |
| | | |
| | | |
| | |
| Money Market Funds and Cash Equivalents | |
$ | 3,472,094 | | |
$ | 3,472,094 | | |
$ | - | | |
$ | - | |
| U.S. Government Agency Securities | |
| 2,691,918 | | |
| 2,691,918 | | |
| - | | |
| - | |
| Corporate Securities | |
| 6,057,267 | | |
| - | | |
| 6,057,267 | | |
| - | |
| Commercial Paper | |
| 3,234,972 | | |
| - | | |
| 3,234,972 | | |
| - | |
| Subtotal | |
| 11,984,157 | | |
| 2,691,918 | | |
| 9,292,239 | | |
| - | |
| Total December 31, 2019 | |
$ | 15,456,251 | | |
$ | 6,164,012 | | |
$ | 9,292,239 | | |
$ | - | |
|
| Schedule of other prepaid expenses |
| | |
September 30,
2020 | | |
December 31,
2019 | |
| Deposit on equipment | |
$ | 500,822 | | |
$ | - | |
| Insurance | |
| 286,241 | | |
| 244,828 | |
| Subscription fees | |
| 132,982 | | |
| 97,983 | |
| Software costs | |
| 372,454 | | |
| 10,081 | |
| Other | |
| 47,740 | | |
| 93,523 | |
| Total | |
$ | 1,340,239 | | |
$ | 446,415 | |
|
| Schedule of inventories |
| | |
September 30, 2020 | | |
December 31, 2019 | |
| Raw materials | |
$ | - | | |
$ | 6,893 | |
| Finished goods | |
| 351,542 | | |
| 461,735 | |
| Inventory reserve | |
| (150,836 | ) | |
| (130,163 | ) |
| Total | |
$ | 200,706 | | |
$ | 338,465 | |
|
| Schedule of accrued expenses |
| | |
September 30, 2020 | | |
December 31, 2019 | |
| Professional and consulting fees | |
$ | 618,472 | | |
$ | 214,777 | |
| Accrued payroll and payroll taxes | |
| 1,603,245 | | |
| 1,287,047 | |
| Clinical trial related | |
| 687 | | |
| 2,435,953 | |
| Manufacturing development related | |
| 230,248 | | |
| 806,032 | |
| Other | |
| 64,189 | | |
| 54,666 | |
| Total | |
$ | 2,516,841 | | |
$ | 4,798,475 | |
|
| Schedule of anti-dilutive securities excluded from calculation of diluted net loss per share |
| | |
Nine Months Ended September 30, | |
| | |
2020 | | |
2019 | |
| | |
(Number of Shares of Common Stock Issuable) | |
| Series C-3 non-voting preferred stock | |
| 104,000 | | |
| 108,000 | |
| Series E non-voting preferred stock | |
| 391,953 | | |
| 391,953 | |
| Series G non-voting preferred stock | |
| 5,560,137 | | |
| 5,560,137 | |
| Restricted stock units | |
| - | | |
| 8,411 | |
| Shares issuable for payment of deferred board compensation | |
| 45,326 | | |
| 31,498 | |
| Shares underlying outstanding warrants | |
| 183,148 | | |
| 344,828 | |
| Shares underlying outstanding stock options | |
| 2,427,687 | | |
| 1,435,110 | |
| Total potentially dilutive shares | |
| 8,712,251 | | |
| 7,879,937 | |
|